Clinical trials: Cancer of the Fallopian Tube
Fallopian Tube Cancer, Ovarian Cancer
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00838656
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 4 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- Warwick Medical School
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I trial studies the side effects of genetically modified T cells and decitabine in treating patients with recurrent or refractory epithelial or non-epithelial ovarian, primary peritoneal, or fallopian tube cancer that…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03017131
- Testing
- Aldesleukin, Cyclophosphamide, Decitabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
This phase II trial studies how well computed tomography perfusion imaging works in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer who are receiving bevacizumab.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03412630
- Testing
- Computed Tomography Perfusion Imaging
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Epithelial Ovarian Cancer, Fallopian Tube Neoplasms
SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- SUROVA (NCT06223763)
- Testing
- Cytoreductive surgery, Neoadjuvant chemotherapy, Adjuvant chemotherapy
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer
Validation of a Nutrition Screening Tool
The objective of this study is to evaluate the sensitivity and specificity of two nutrition screening tools to identify inpatients with malnutrition or at risk of malnutrition.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer, Endometrial Cancer, Esophageal Cancer
- Trial name
- NCT01851928
- Where
- United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Ovarian Cancer, Fallopian Tube Cancer
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Trial name
- NCT03056833
- Testing
- ribociclib, Paclitaxel, Carboplatin
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Ronald Buckanovich
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003385
- Testing
- carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride
- Where
- 8 sites in United States, Norway
- Volunteers
- 48 people
- Sponsor
- Gynecologic Oncology Group
Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Although immunotherapy has revolutionized the treatment of many cancers, ovarian cancer patients have not yet benefitted from the advances.
- Conditions
- Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT04611126
- Testing
- Ipilimumab, Cyclophosphamid, Fludarabine Phosphate
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Inge Marie Svane
Ovarian Cancer
Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India
This is a non-interventional, cross-sectional, multicentre, observational study planned to be conducted at 15 sites across all geographical regions of India.
- Trial name
- BRCA (NCT03471572)
- Where
- 8 sites in India
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Endometrial Carcinoma, Ovarian Carcinoma
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to standard platinum-based chemotherapy…
- Conditions
- Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- AL3818 (NCT02584478)
- Testing
- AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 41 sites in United States, China and 4 more
- Volunteers
- 294 people
- Sponsor
- Advenchen Laboratories, LLC
FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer
- Conditions
- FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07322094
- Testing
- TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- TORL Biotherapeutics, LLC
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study of Long-Term Responders on Olaparib
This is an observational and sample collection study involving patients (alive or deceased) from several clinical trials who had received the investigational drug, olaparib in other research studies.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- OLALA (NCT02489058)
- Where
- 8 sites in Australia, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- University Health Network, Toronto
Fallopian Tube Cancer, Ovarian Cancer
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003634
- Testing
- oregovomab
- Where
- 46 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- AltaRex
Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.
- Conditions
- Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma
- Trial name
- ONTAK (NCT00880360)
- Testing
- Ontak
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00616941
- Testing
- NY-ESO-1 OLP4, NY-ESO-1 OLP4 + Montanide, NY-ESO-1 OLP4 + Montanide + Poly-ICLC
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Ludwig Institute for Cancer Research
Gynecological Tumor, Ovarian Cancer
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
To determine the best method to prevent CINV caused by TC regimen in patients with gynecological malignant tumor. Paclitaxel-carboplatin (TC) is the most widely used regimen for gynecologic malignancies, yet chemotherapy-induced…
- Conditions
- Gynecological Tumor, Ovarian Cancer, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT06007586
- Testing
- Aprepitant Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients with…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00019461
- Testing
- carboxyamidotriazole, chemotherapy
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)